Form 8-K - Current report:
SEC Accession No. 0000950170-24-131074
Filing Date
2024-11-26
Accepted
2024-11-26 16:40:05
Documents
13
Period of Report
2024-11-26
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kytx-20241126.htm   iXBRL 8-K 42788
2 EX-10.1 kytx-ex10_1.htm EX-10.1 71391
3 GRAPHIC img244929906_0.jpg GRAPHIC 9872
  Complete submission text file 0000950170-24-131074.txt   255904

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kytx-20241126.xsd EX-101.SCH 24834
15 EXTRACTED XBRL INSTANCE DOCUMENT kytx-20241126_htm.xml XML 4715
Mailing Address 5980 HORTON STREET SUITE 550 EMERYVILLE CA 94608
Business Address 5980 HORTON STREET SUITE 550 EMERYVILLE CA 94608 5106268331
Kyverna Therapeutics, Inc. (Filer) CIK: 0001994702 (see all company filings)

EIN.: 831365441 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41947 | Film No.: 241504636
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)